Dec Quarterly Update and Appendix 4C

Phylogica Appoints New Scientific Advisory Board Member

Federal R&D Tax Credit Received

PYC Pivot to Platform – BioShowcase Presentation

FPP Results Effective in Delivering Peptide Cancer Vaccine

Appointment of Non-Executive Director and Appendix 3X

Phylogica Strategic Update – Pivot to Platform

Final Director’s Interest Notice

Appendix 3B and 3Y’s

Company Presentation – 2017 Annual General Meeting

Chairman’s Address – 2017 Annual General Meeting

Results of Annual General Meeting

Paul Watt Joins Phylogica Scientific Advisory Board

Company Presentation – BIO Europe November 2017

Corporate Governance Statement

Annual Report to shareholders

Notice of Annual General Meeting/Proxy Form

Appendix 3B and Appendix 3Y

Appendix 3X and Appendix 3Z

Operational Update September Quarter and Appendix 4C

Establishment and Appointments to Scientific Advisory Board

Becoming a substantial holder

Appointment of Non-Executive Director

Change in substantial holding

Investor Presentation – October 2017

PYC Granted US Patent for Peptides Entering Brain Cells

June 2017 Annual Financial Statements

Finance News Network Interview with the CEO

Sydney Investor Presentation

New Delivery Vehicles Show Improved Performance Inside Cells

Investor Presentation

Appendix 4E – Preliminary Final Report 30 June 2017

Phylogica Investor Briefing – August 2017 Amended

Phylogica Investor Briefing – August 2017

Appendix 4C – quarterly

Appointment of Company Secretary and change of Registered Office

Operational Update June Quarter

S 708A cleansing notice for option exercise

Application for listing upon option exercise

Appendix 3B option exercise

S708 Cleansing Notice option issue

Executive Director Remuneration

Becoming a substantial holder

Ceasing to be a substantial holder

Change in substantial holding

Change of Director’s Interest Notice

CEO and CSO Appointments

Share issue S708A cleansing notice

Application for listing $5m placement

S 708(A) notice upon issue of shares

Appendix 3B application for listing

Change of Director’s Interest Notice

S708A notice upon the issue of shares

S708 Notice for issue of shares

Appendix 3B application for listing

Appendix 4C – quarterly

Final Director’s Interest Notice

Initial Director’s Interest Notice (two directors)

Operational Update March Quarter

Resignation of Secretary

Clarification on Security Cancellations

ASIC Form 484 Share Cancellation

Change of Director’s Interest Notice

Half Yearly Report and Accounts

Appendix 4C – quarterly

Change of Director’s Interest Notice

Change in substantial holding

Change of Director’s Interest Notice

Investor Presentation – Biotech Showcase – San Francisco

Notice of change of interests of substantial holder

Operational Update

Genentech extends research collaboration period

NHMRC Grant Awarded to Collaborators

Change of Director’s Interest Notice

Annual General Meeting Results

Final Director’s Interest Notice

Director Resignation

AGM Presentation to Shareholders

Chair’s Address to Shareholders

Becoming a substantial holder

Appendix 4C – quarterly

Notice of Annual General Meeting/Proxy Form

Annual Report to shareholders

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Operational Update

Initial Director’s Interest Notice

Director Appointment

Corporate Governance Statement